Dicot's strategy is to build a wide patent protection for current and future drug candidates.

As of today, Dicot has granted patents or patent applications within two patent families. The first patent family covers natural and synthetic Libiguin, the natural sources of Libiguin from plants, the use of Libiguin for the treatment of sexual dysfunctions and the process of preparation and administration of Libiguin to patients.

The second patent family includes processes for the semi-synthetic production of Libiguin.

Dicot's patent strategy is global and covers the markets that are assessed to be clinically and commercially relevant to the product pipeline.